Literature DB >> 12745310

Nicotine, alcohol and drug dependence, and psychiatric comorbidity--results of a national household survey.

M Farrell1, S Howes, P Bebbington, T Brugha, R Jenkins, G Lewis, J Marsden, C Taylor, H Meltzer.   

Abstract

There is a well-recognized relationship between substance use disorders and other psychiatric disorders. This relationship has been well documented in a range of population-based studies. This study aims to report on consumption patterns of and dependence on nicotine, alcohol, and non-prescribed drugs and to report on the levels of psychiatric morbidity in these groups. A national household study of psychiatric morbidity was conducted in England and Wales. Psychiatric assessment was based on the Clinical Interview Schedule-Revised (CIS-R). Measures of nicotine, alcohol and drug use and dependence were obtained. This paper compares the levels of psychiatric morbidity in the non-dependent and the nicotine-, alcohol- and drug-dependent cases. Twelve per cent of the non-dependent population were assessed as having any psychiatric disorder compared with 22% of the nicotine-dependent, 30% of the alcohol-dependent, and 45% of the drug-dependent population. There is a clear relationship between dependence on nicotine, alcohol, and drugs and other psychiatric morbidity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745310     DOI: 10.1080/0954026021000045949

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  16 in total

1.  Training in Substance-Related and Addictive Disorders, Part 1: Overview of Clinical Practice and General Recommendations.

Authors:  Gilles Fleury; Robert Milin; David Crockford; Leslie Buckley; Dara Charney; Tony P George; Nady el-Guebaly
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

2.  Inverted U shaped effect of nicotine on the severity of depressive symptoms: A population-based survey.

Authors:  Ammar W Ashor
Journal:  J Young Pharm       Date:  2013-07-08

Review 3.  Prevalence of the addictions: a problem of the majority or the minority?

Authors:  Steve Sussman; Nadra Lisha; Mark Griffiths
Journal:  Eval Health Prof       Date:  2010-09-27       Impact factor: 2.651

4.  Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.

Authors:  Yvonne Buggy; Victoria Cornelius; Carole Fogg; Rachna Kasliwal; Deborah Layton; Saad A W Shakir
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

5.  Service utilization during and after outpatient treatment for comorbid substance use disorder and depression.

Authors:  Matthew J Worley; Ryan S Trim; Susan R Tate; Jessica E Hall; Sandra A Brown
Journal:  J Subst Abuse Treat       Date:  2010-07-03

6.  One-year follow-up evaluation of the Project Towards No Drug Abuse (TND) dissemination trial.

Authors:  Louise A Rohrbach; Ping Sun; Steve Sussman
Journal:  Prev Med       Date:  2010-07-23       Impact factor: 4.018

7.  The validity of drug use responses in a household survey in Puerto Rico: comparison of survey responses with urinalysis.

Authors:  H M Colón; C M Pérez; M Meléndez; E Marrero; A P Ortiz; E Suárez
Journal:  Addict Behav       Date:  2010-02-10       Impact factor: 3.913

Review 8.  Oxytocin and opioid addiction revisited: old drug, new applications.

Authors:  Panos Zanos; Polymnia Georgiou; Carol Weber; Fiona Robinson; Christos Kouimtsidis; Ramin Niforooshan; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2017-04-06       Impact factor: 8.739

9.  The Relationship between Anxiety Sensitivity and Posttraumatic Stress Disorder: What is the Impact of Nicotine Withdrawal?

Authors:  Anu Asnaani; Samantha G Farris; Joseph K Carpenter; Laurie J Zandberg; Edna B Foa
Journal:  Cognit Ther Res       Date:  2015-04-19

10.  Changes in millennial adolescent mental health and health-related behaviours over 10 years: a population cohort comparison study.

Authors:  Praveetha Patalay; Suzanne H Gage
Journal:  Int J Epidemiol       Date:  2019-10-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.